Industry Trends

August 2020

See what has been happening in Asia’s pharma and personal care industries over the last weeks. What are experts and industry magazines talking about?

What has been happening?

Derma and natural beauty trends are here to stay post-COVID-19, mouthwashes could reduce coronavirus transmission, Philippines’ FDA approves China’s COVID-19 drug for treatment of fever, lung toxins and more.  Find out what journals and industry experts have been discussing in the last four weeks.

Latest Industry Articles

Safety and comfort: Derma and natural beauty trends are here to stay post-COVID-19
CosmeticsDesign-Asia

Consumers will increasingly seek out the safety of cosmeceuticals and the comfort of natural products in the long-term due to the novel coronavirus (COVID-19) disruptions, says ingredients company BASF.
Mouthwashes could reduce coronavirus transmission
Cosmetics Business

In testing of eight commercial mouthwashes, German researchers found the concentration of Sars-Cov-2 was reduced.
Philippines' FDA approves China's COVID-19 drug for treatment of fever, lung toxins

GMA News Online

The Food and Drug Administration (FDA) has approved a drug, now being used in China to treat COVID-19, for Philippine use to treat lung toxins, fever and other related symptoms. FDA Director General Eric Domingo, however, said that the Lian Hua Qing Weng has yet to be approved in Philippines as a treatment for the coronavirus disease.

Pfizer inks manufacturing deal with Gilead for COVID-19 med remdesivir
PharmaTimes World News

Pfizer becomes one of multiple external manufacturing organisations supporting scale-up of treatment.
‘High growth potential’: Shiseido seeks to expand business in China’s through booming beauty device segment
CosmeticsDesign-Asia

Japanese cosmetics giant Shiseido Company is eyeing huge opportunities in China’s beauty device market, which has been growing rapidly amid the novel coronavirus (COVID-19) pandemic.
China policy: Regulator publishes two more drafts detailing safety assessment and classification for cosmetic products
CosmeticsDesign-Asia

China’s National Medical Products Administration has released two additional drafts detailing safety and classification requirements under the new Cosmetic Supervision and Administration Regulation (CSAR).
Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding
FiercePharma News

Eli Lilly, Pfizer, Merck among Big Pharma losers in China’s latest round of procurement bidding esagonowsky
Positive long-term vital signs for China's global health care players
South China Morning Post

China’s health care industry is facing stricter overseas scrutiny and pressure in the global supply chain, but the Chinese players will survive and may even become more competitive, according to a new industry report.
Regulatory issues limit Indonesia's role in global pharma value chain
The Jakarta Post

CIPS is of the view that the Indonesian pharmaceutical industry has the potential to take advantage of slowing manufacturing activities in China because of restrictions during the pandemic.

Related Articles & Trends

Pharma & Personal Care Trends – November 2024

Pharma & Personal Care Trends – November 2024

Beauty 4.0: The state of the menopausal beauty market, New skin care line to address interest in Traditional Chinese Medicine and well-being surges, Benefits of transitioning to E-Cigarettes, and more. See what industry experts have been discussing in the last four weeks.

Pharma & Personal Care Trends – October 2024

Pharma & Personal Care Trends – October 2024

Sustainable cosmetic packaging innovations at Luxe Pack 2024, One or two-dose HPV vaccination, 3 ways to maintain glowy skin, and more. See what industry experts have been discussing in the last four weeks.

Pharma & Personal Care Trends – September 2024

Pharma & Personal Care Trends – September 2024

Rutin emerges as a sustainable alternative in sunscreen formulations, Infusing sustainability and transparency into skin care, Formulating menopausal skin care, and more. See what industry experts have been discussing in the last four weeks.

Industry News . Once a month . No spam